Jane Street Group, LLC Glycomimetics Inc Transaction History

Jane Street Group, LLC

$72.9 Billion
Q1 2024

A detailed history of Jane Street Group, LLC transactions in Glycomimetics Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 289,275 shares of GLYC stock, worth $95,460. This represents 0.0% of its overall portfolio holdings.

Number of Shares

289,275

Previous 57,143 406.23%

Holding current value

$95,460

Previous $134,000 547.01%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $591,936 - $810,140	232,132 Added 406.23%	289,275 $867,000
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $42,008 - $94,427	37,176 Added 186.19%	57,143 $134,000
Q3 2023 Nov 14, 2023	BUY	$1.29 - $1.73 $25,757 - $34,542	19,967 New	19,967 $29,000
Q1 2023 May 15, 2023	BUY	$1.25 - $4.05 $2,415 - $7,824	1,932 Added 7.79%	26,732 $33,000
Q4 2022 Feb 14, 2023	BUY	$0.67 - $3.03 $16,616 - $75,144	24,800 New	24,800 $75,000

Q2 2022 Aug 16, 2022	BUY	$0.54 - $1.15 $10,343 - $22,027	19,154 New	19,154 $11,000
Q3 2021 Nov 16, 2021	SELL	$1.8 - $2.39 $69,555 - $92,354	-38,642 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.16 - $3.18 $58,533 - $86,174	27,099 Added 234.77%	38,642 $90,000
Q1 2021 May 18, 2021	BUY	$2.89 - $4.22 $33,359 - $48,711	11,543 New	11,543 $35,000
Q2 2020 Aug 17, 2020	SELL	$2.06 - $3.76 $33,464 - $61,081	-16,245 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.83 - $5.41 $29,728 - $87,885	16,245 New	16,245 $37,000
Q1 2019 May 16, 2019	SELL	$9.96 - $13.44 $120,247 - $162,261	-12,073 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$8.47 - $14.71 $102,258 - $177,593	12,073 New	12,073 $114,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

36.8M

Call Options Held

969K

Put Options Held

636K

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $17.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Glycomimetics Inc Transaction History